Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
GlaxoSmithKline
National Institutes of Health Clinical Center (CC)
City of Hope Medical Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
AstraZeneca
Eisai Inc.
BioNTech SE
Gilead Sciences
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Merck Sharp & Dohme LLC
OHSU Knight Cancer Institute
Hansoh BioMedical R&D Company
Jiangsu Simcere Pharmaceutical Co., Ltd.
Mural Oncology, Inc
Eisai Inc.
Yonsei University
Mayo Clinic
Hutchmed
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Mayo Clinic
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Universitaire Ziekenhuizen KU Leuven
National Cancer Institute (NCI)
ARCAGY/ GINECO GROUP
Pfizer
Barretos Cancer Hospital
Odense University Hospital
Holy Name Medical Center, Inc.
Ruhr University of Bochum
Ruhr University of Bochum
Peking University People's Hospital
GOG Foundation
Novartis
Fondazione del Piemonte per l'Oncologia
National Cancer Institute (NCI)
Swiss Cancer Institute
GOG Foundation
Mayo Clinic
AGC Biologics S.p.A.
AGC Biologics S.p.A.
AEterna Zentaris
National Cancer Institute (NCI)
University of Texas Southwestern Medical Center
GlaxoSmithKline
Odense University Hospital
GOG Foundation
Columbia University
R-Pharm